We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
Read MoreHide Full Article
Key Takeaways
SNY is trading below its 50- and 200-day moving averages, raising investor concerns about stock direction.
Dupixent drives SNY revenues with approvals in eight diseases.
Estimates for SNY's 2025 and 2026 earnings have risen, supported by new launches and pipeline momentum.
Sanofi’s (SNY - Free Report) stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the 200-day moving average of $50.71.
When a stock's price is below its 200-day moving average, it can be interpreted as a potential sign of weakness or a bearish trend in the stock. With Sanofi’s stock price going below its 50-day and 200-day moving averages, investors holding the stock are confused about whether they should consider selling the stock.
Let’s understand the company’s strengths and weaknesses to better analyze how to play Sanofi stock amid this scenario.
Dupixent: A Key Top-Line Driver for SNY
Sanofi and Regeneron’s (REGN - Free Report) immunology drug, Dupixent, has become the key top-line driver as it enjoys strong demand across all approved indications and geographies. Dupixent is now approved in several countries, including the United States and the EU, for six type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease (COPD). Sanofi/Regeneron’s Dupixent was approved for its seventh indication, chronic spontaneous urticaria, in the United States in April 2025 and for its eighth indication, bullous pemphigoid, in June.
Dupixent’s strong sales growth is being driven by demand across all geographies, newly approved indications and demographics. New uses, increased penetration in approved indications and further geographic expansion are expected to drive Dupixent’s sales in future quarters. Sanofi expects Dupixent to achieve around €22 billion in sales in 2030.
SNY Boasts a Strong Vaccine Segment
Sanofi possesses one of the world’s leading vaccine operations, with total annual sales of more than €5 billion in the past five years. Its Vaccines unit has delivered mid-to-high-single-digit sales growth since 2018. In 2024, Sanofi’s Vaccines segment recorded sales growth of 13.5% at CER, exceeding expectations of growing at a high single-digit range due to the successful rollout of Beyfortus, which reached €1.7 billion in sales. In the first quarter of 2025, total vaccine sales increased 11.4%. Sanofi continues to expand its vaccine business further. Some vaccine candidates that are in phase III development include a 21-valent pneumococcal conjugate vaccine and a next-generation rabies vaccine. Sanofi expects annual net sales to be more than €10 billion from its Vaccines unit by 2030, backed by its innovation efforts.
SNY’s New Products & Strong Pipeline Can Drive Long-Term Growth
Sanofi’s new products, like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [(AZN - Free Report) ]), Pompe disease therapy, Nexviazyme, and chronic graft-versus-host disease drug, Rezurock, are contributing to top-line growth. Revenues from these products are offsetting the impact of generic competition on Aubagio's sales.
Sanofi is investing in these launches to optimize their success. Beyfortus achieved blockbuster sales in its first full year of sales in 2024. Altuviiio is expected to achieve blockbuster sales in 2025.
Sanofi has a strong immunology and neuro-inflammation pipeline, which includes 12 potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.
A key new product, Qfitlia (fitusiran), was approved by the FDA in March 2025 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B. FDA decisions on tolebrutinib for non-relapsing secondary progressive multiple sclerosis and rilzabrutinib for immune thrombocytopenia are expected this year.
SNY’s Several Headwinds
Generic versions of the key drug, Aubagio, were launched in the United States in March 2023 and in Europe at the end of September 2023, which significantly eroded the drug’s sales in 2023 and 2024. Aubagio sales are expected to continue to decline in 2025.
Sales of Sanofi’s influenza vaccines, which represented 30.8% of vaccines net sales, declined 1.4% in 2024 due to rising competitive and pricing pressure. The challenges are expected to continue. In the first quarter of 2025, influenza vaccine sales declined 1.4%. Sanofi believes that the influenza market is likely to have several new competitive entrants, both from standalone flu mRNA and COVID-flu combinations. In addition, intense pricing pressure and lower vaccine coverage can hurt sales of influenza vaccines in future quarters.
Competition for Beyfortus, which represented 20.3% of vaccine sales in 2024, may increase with the launch of Merck’s (MRK - Free Report) new monoclonal antibody for RSV, Enflonsia, which was approved by the FDA earlier this month.
SNY’s Price, Valuation & Estimate Movement
Sanofi’s stock has risen 3.1% year to date against a decrease of 1.2% for the industry. The stock has also outperformed the sector and the S&P 500, as seen in the chart below.
SNY Stock Outperforms Industry, Sector and S&P 500
Image Source: Zacks Investment Research
From a valuation standpoint, Sanofi appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 10.15 forward earnings, lower than 14.81 for the industry. The stock also trades lower than its 5-year mean of 11.68. The stock is also much cheaper than other large drugmakers like Novo Nordisk, AstraZeneca, J&J, AbbVie and Lilly.
SNY Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $4.43 per share to $4.56 per share over the past 60 days. For 2026, earnings estimates have risen from $4.86 per share to $4.94 per share over the same timeframe.
SNY Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in SNY Stock
Sanofi faces its share of headwinds, like generic erosion of key drug Aubagio in all key markets and lower sales from mature products, which are hurting sales. Other headwinds include weak sales of influenza vaccines and regular negative pipeline developments.
In 2025, Sanofi expects sales to rise by a mid-to-high single-digit percentage at CER. Earnings are expected to rebound strongly, with an expectation of a low double-digit percentage growth at CER (before stock buyback) in 2025 versus 4.1% in 2024.
Sanofi’s price appreciation, rising estimates, reasonable valuation, improving top-line performance, potential contributions from new product launches and positive pipeline progress are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested despite the stock's price going below its 50 and 200-day moving averages.
Image: Bigstock
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
Key Takeaways
Sanofi’s (SNY - Free Report) stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the 200-day moving average of $50.71.
When a stock's price is below its 200-day moving average, it can be interpreted as a potential sign of weakness or a bearish trend in the stock. With Sanofi’s stock price going below its 50-day and 200-day moving averages, investors holding the stock are confused about whether they should consider selling the stock.
Let’s understand the company’s strengths and weaknesses to better analyze how to play Sanofi stock amid this scenario.
Dupixent: A Key Top-Line Driver for SNY
Sanofi and Regeneron’s (REGN - Free Report) immunology drug, Dupixent, has become the key top-line driver as it enjoys strong demand across all approved indications and geographies. Dupixent is now approved in several countries, including the United States and the EU, for six type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease (COPD). Sanofi/Regeneron’s Dupixent was approved for its seventh indication, chronic spontaneous urticaria, in the United States in April 2025 and for its eighth indication, bullous pemphigoid, in June.
Dupixent’s strong sales growth is being driven by demand across all geographies, newly approved indications and demographics. New uses, increased penetration in approved indications and further geographic expansion are expected to drive Dupixent’s sales in future quarters. Sanofi expects Dupixent to achieve around €22 billion in sales in 2030.
SNY Boasts a Strong Vaccine Segment
Sanofi possesses one of the world’s leading vaccine operations, with total annual sales of more than €5 billion in the past five years. Its Vaccines unit has delivered mid-to-high-single-digit sales growth since 2018. In 2024, Sanofi’s Vaccines segment recorded sales growth of 13.5% at CER, exceeding expectations of growing at a high single-digit range due to the successful rollout of Beyfortus, which reached €1.7 billion in sales. In the first quarter of 2025, total vaccine sales increased 11.4%. Sanofi continues to expand its vaccine business further. Some vaccine candidates that are in phase III development include a 21-valent pneumococcal conjugate vaccine and a next-generation rabies vaccine. Sanofi expects annual net sales to be more than €10 billion from its Vaccines unit by 2030, backed by its innovation efforts.
SNY’s New Products & Strong Pipeline Can Drive Long-Term Growth
Sanofi’s new products, like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [(AZN - Free Report) ]), Pompe disease therapy, Nexviazyme, and chronic graft-versus-host disease drug, Rezurock, are contributing to top-line growth. Revenues from these products are offsetting the impact of generic competition on Aubagio's sales.
Sanofi is investing in these launches to optimize their success. Beyfortus achieved blockbuster sales in its first full year of sales in 2024. Altuviiio is expected to achieve blockbuster sales in 2025.
Sanofi has a strong immunology and neuro-inflammation pipeline, which includes 12 potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.
A key new product, Qfitlia (fitusiran), was approved by the FDA in March 2025 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B. FDA decisions on tolebrutinib for non-relapsing secondary progressive multiple sclerosis and rilzabrutinib for immune thrombocytopenia are expected this year.
SNY’s Several Headwinds
Generic versions of the key drug, Aubagio, were launched in the United States in March 2023 and in Europe at the end of September 2023, which significantly eroded the drug’s sales in 2023 and 2024. Aubagio sales are expected to continue to decline in 2025.
Sales of Sanofi’s influenza vaccines, which represented 30.8% of vaccines net sales, declined 1.4% in 2024 due to rising competitive and pricing pressure. The challenges are expected to continue. In the first quarter of 2025, influenza vaccine sales declined 1.4%. Sanofi believes that the influenza market is likely to have several new competitive entrants, both from standalone flu mRNA and COVID-flu combinations. In addition, intense pricing pressure and lower vaccine coverage can hurt sales of influenza vaccines in future quarters.
Competition for Beyfortus, which represented 20.3% of vaccine sales in 2024, may increase with the launch of Merck’s (MRK - Free Report) new monoclonal antibody for RSV, Enflonsia, which was approved by the FDA earlier this month.
SNY’s Price, Valuation & Estimate Movement
Sanofi’s stock has risen 3.1% year to date against a decrease of 1.2% for the industry. The stock has also outperformed the sector and the S&P 500, as seen in the chart below.
SNY Stock Outperforms Industry, Sector and S&P 500
From a valuation standpoint, Sanofi appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 10.15 forward earnings, lower than 14.81 for the industry. The stock also trades lower than its 5-year mean of 11.68. The stock is also much cheaper than other large drugmakers like Novo Nordisk, AstraZeneca, J&J, AbbVie and Lilly.
SNY Stock Valuation
The Zacks Consensus Estimate for 2025 earnings has risen from $4.43 per share to $4.56 per share over the past 60 days. For 2026, earnings estimates have risen from $4.86 per share to $4.94 per share over the same timeframe.
SNY Estimate Movement
Stay Invested in SNY Stock
Sanofi faces its share of headwinds, like generic erosion of key drug Aubagio in all key markets and lower sales from mature products, which are hurting sales. Other headwinds include weak sales of influenza vaccines and regular negative pipeline developments.
However, Sanofi has increased R&D investments and is achieving significant progress with its pipeline. It has also been active on the M&A front. In less than two months, it announced proposed acquisitions of Blueprint Medicines and Vigil Neuroscience. While the BPMC deal will expand Sanofi’s presence in rare immunological diseases, the VIGL deal will boost Sanofi’s neurology pipeline.
In 2025, Sanofi expects sales to rise by a mid-to-high single-digit percentage at CER. Earnings are expected to rebound strongly, with an expectation of a low double-digit percentage growth at CER (before stock buyback) in 2025 versus 4.1% in 2024.
Sanofi’s price appreciation, rising estimates, reasonable valuation, improving top-line performance, potential contributions from new product launches and positive pipeline progress are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested despite the stock's price going below its 50 and 200-day moving averages.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.